Skip to main content
OpenTrials
Completed

NCT Number: NCT04682574

Role of Mega Dose of Vitamin C in Critical COVID-19 Patients

Vitamin C (ascorbic acid) is a water-soluble vitamin having anti-inflammatory, immunomodulatory, anti-oxidative, antithrombotic and antiviral properties. Considering these effects vitamin C should have beneficial impact in patients suffering from sepsis and acute respiratory distress syndrome (ARDS). The current study is designed to assess the beneficial effects of Vitamin C in COVID-19 infected patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Corona Virus Infection Coronaviridae Infections Coronavirus Infections Infections Nidovirales Infections RNA Virus Infections Virus Diseases

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Bahria Town International Hospital

Lahore, Punjab Province, 54000, Pakistan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

critically ill patients admitted in ICU

Exclusion criteria

allergic to Vitamin C didnt given the consent

Treatment and study plan

Vitamin C

Drug

mega dose is given to the selected critically ill patients

Primary outcomes

  1. Partial pressure of Oxygen in arterial blood to fraction of inspired Oxygen (P/F ratio)

    Time frame: 1 and 4th day

  2. Survival analysis

    Time frame: 28 days follow up

Secondary outcomes

  1. Length of Hospital stay

    Time frame: Admission to discharge

  2. Need for intubation

    Time frame: 28 days

    number of intubations needed in both groups.

  3. Inflammatory markers

    Time frame: before the start of treatment (day 1) and on day 4

    comparison of the inflammatory markers, CRP, D.Dimer, Procalcitonin, LDH, TLC and hematological variables at day four after the intervention started.

  4. APACHE II score

    Time frame: before the start of treatment (day 1) and on day 4

Sponsors and collaborators

Lead sponsor

University of Lahore

Other

Registry information

Official study title

Effects of Mega Dose Vitamin C in Critically Ill COVID-19 Patients: A Randomized Control Trial

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Dec 23, 2020
Registry last updated
May 6, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.